Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
PP&E Net
Adaptimmune Therapeutics PLC
PP&E Net Peer Comparison
Competitive PP&E Net Analysis
Latest Figures & CAGR of Competitors
Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
PP&E Net
$67.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
PP&E Net
$13m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
PP&E Net
$95.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
PP&E Net
$24.8m
|
CAGR 3-Years
58%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
PP&E Net
£42.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
PP&E Net
£509.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
See Also
What is Adaptimmune Therapeutics PLC's PP&E Net?
PP&E Net
67.7m
USD
Based on the financial report for Mar 31, 2024, Adaptimmune Therapeutics PLC's PP&E Net amounts to 67.7m USD.
What is Adaptimmune Therapeutics PLC's PP&E Net growth rate?
PP&E Net CAGR 5Y
2%
Over the last year, the PP&E Net growth was -6%. The average annual PP&E Net growth rates for Adaptimmune Therapeutics PLC have been 14% over the past three years , 2% over the past five years .